Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety, efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in subjects with Primary Humoral Immunodeficiency (PHID).


Clinical Trial Description

This was a prospective, open-label, single-arm, historically controlled, multicenter phase 3 study measuring the safety, efficacy and pharmacokinetics and tolerability of GC5107 in subjects with Primary Humoral Immunodeficiency disease (PHID). Subjects received intravenous infusions of the investigational product at the same dose and interval as used for their previous Immunoglobulin intravenous (IVIG) maintenance therapy. GC5107 was administered every 21 or 28 days for a period of 12 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02783482
Study type Interventional
Source GC Biopharma Corp
Contact
Status Completed
Phase Phase 3
Start date October 2016
Completion date July 2019

See also
  Status Clinical Trial Phase
Completed NCT04798677 - Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine N/A
Completed NCT00598481 - ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID Phase 2
Completed NCT00468273 - A Clinical Study of Intravenous Immunoglobulin Phase 3
Completed NCT01727895 - Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans N/A
Enrolling by invitation NCT03478670 - Strimvelis Registry Study to Follow-up Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)
Terminated NCT00006054 - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies N/A
Recruiting NCT03920735 - Retrospective Non-interventional Analysis of Opportunistic Infections in Immunocompromised and Frail Patients
Completed NCT00001438 - A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes Phase 2
Terminated NCT00811174 - Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases Phase 3
Completed NCT00006131 - Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster N/A
Recruiting NCT02735824 - Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies
Completed NCT02554630 - Novel Mechanisms and Approaches to Treat Neonatal Sepsis
Recruiting NCT03835312 - Sequential Transplantation of UCBSCs and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency T1DM N/A
Completed NCT00176865 - Stem Cell Transplant for Immunologic or Histiocytic Disorders Phase 2
Completed NCT00001646 - Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis Phase 3
Completed NCT02630082 - Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru N/A
Completed NCT00001158 - Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System N/A